1 / 50

Enhancement of Bioavailability of Atorvastatin Calcium by Micro and Nanoparticle Preparation

This study focuses on the design and evaluation of colloidal particles of Atorvastatin calcium to improve its bioavailability. The use of biodegradable polymers and various techniques such as micro and nanoparticle formation are explored. The study includes in vitro and in vivo experiments to determine the drug content, release kinetics, and pharmacokinetic parameters.

jacobedwards
Télécharger la présentation

Enhancement of Bioavailability of Atorvastatin Calcium by Micro and Nanoparticle Preparation

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Enhancement Of Bioavailability Of Atorvastatin Calcium byMicro and Nanoparicle preparation- Design and Evaluation Dr.K.Senthilkumaran INTI International University College

  2. S.Dinesh kumar, M.Nappinnai • Department of Pharmaceutics, C.L.Baid Metha College of Pharmacy, • Chennai, India.

  3. Introduction • Bioavailability :is the true rate and extent of therapeutically active drug, which reaches the systemic circulation and is available at the site of action from an administered dosage form.

  4. Bioavailability studies provide other useful pharmacokinetic information related to distribution, elimination and metabolism of drugs in the body. • Bioavailability data may also provide information indirectly about some properties of a drug substance - such as membrane permeability

  5. Absolute bioavailability of a drug is 1 (or 100%) indicates complete absorption of drug.

  6. SIGNIFICANCE OF BIOAVAILABILITY STUDIES • Development of a suitable dosage form for a new drug entity • Determination of influence of excipients, patient related factors, on the efficiency of absorption.

  7. Development of new formulations of the existing drugs. • Development of suitable dosage form for a new drug.

  8. METHODS FOR ASSESSING BIOAVAILABILITY • Pharmacokinetic methods: based on the plasma concentration of the drug and on the assumption that the pharmacokinetic profile reflects the therapeutic effectiveness of a drug • Pharmacodynamic methods: involves direct measurement of drug effect on a pathophysiologic process as a function of time.

  9. REASONS FOR POOR BIOAVAILABILITY • Poor aqueous solubility of the drug • Poor stability of the dissolved drug at physiological pH. • Poor permeation through the biomembranes • Extensive presystemic metabolism.

  10. METHODS TO ENHANCE BIOAVAILABILITY • To enhance the dissolution rate of a drug: • Micro encapsulation • Use of surfactants • Solute-solvent complexations • Solid dispersions • Molecular encapsulations with cyclodextrins

  11. In the present study • Atorvastatin calcium is reported to have low bioavailability of 14% • The low systemic availability is attributed to presystemic clearance in gastro-intestinal mucosa • The drug is rapidly absorbed after oral administration and maximum plasma concentrations occur within 2 hours.

  12. SCOPE OF THE PRESENT WORK • Atorvastatin calcium is formulated as colloidal particles for oral drug delivery with an aim to improve its bioavailability. • Biodegradable polymer poly- lactide co- glycolide was used to prepare the colloidal particles.

  13. Approaches • Incorporation of the drug into colloidal particles may protect it from the first pass effect, which may lead to an increased bioavailability • Prolonging the release may also improve the bioavailability.

  14. Size reduction of the final formulation in colloidal particles improve absorption leading to improvement in bioavailability.

  15. METHODOLOGY • Preparation of colloidal particles of atorvastatin by using poly lactide- co-glycolide PLGA-resomer RG 50:50 H by solvent evaporation techniques. • Determination of drug content, drug loading and encapsulation efficiency of prepared colloidal particles.

  16. Determination of drug – polymer interaction by FT-IR • In vitro release studies of dissolution release kinetic analysis. • In vivo release study of atorvastatin calcium colloidal particles

  17. Determination of pharmacokinetic parameters. • In vivo pharmacodynamic study

  18. DRUG PROFILE • Structure: Molecular formula: (C 33 H 34 F N 2O 5) 2 Ca. 3 H 2 O Molecular weight: 1209.42 Description: White to off-white crystalline powder. Solubility :Atorvaststin calcium is very slightly soluble in water, freely soluble in methanol. Dose: 10 -40mg daily

  19. PREPARATION OF COLLOIDAL PARTICLES OF ATORVASTATIN CALCIUM • Atorvastatin calcium was prepared into colloidal particles with polylactide – co- glycolide resomer (RG 50:50H) by solvent evaporation method. • 100 mg of PLGA was weighed and dissolved in a mixture of dichloro methane and ethanol in ratio (4:1) • 100 mg of atorvastatin calcium was added to the polymer solution and mixed well.

  20. The above mixture was added drop wise to the (0.4%) preheated 40oC) polyvinyl alcohol in distilled water. • Tween 80 was used for emulsion formation and stabilization. • This mixture was continuously homogenized to yield a oil in water emulsion.

  21. The emulsion was stirred continuously for 3 hours to allow the organic solvent to evaporate and the hardening of atorvastatin calcium colloidal particles to be completed. • The colloidal particles of atrovastatin calcium, were recovered by refrigerated centrifugation/membrane filtration/ lyophilisation

  22. The formulation trials of Drug :polymer

  23. Percentage yield of colloidal particles

  24. Determination of Drug content in colloidal particles • Determination the amount of atorvastatin calcium present in the 100 mg colloidal particles was calculated by using standard calibration graph of atrovastatin calcium in methanol. • The same procedure was triplicated for each formulation

  25. Drug content of Colloidal Particles

  26. From the results of analysis of drug content, drug loading, drug encapsulation formulation F4 was selected for further studies.

  27. Particle size analysis • The particle size of formulated colloidal micro particles were analyzed by Particle size analyzer. • FTIR spectra of the drug, PLGA and the drug loaded PLGA colloidal particles were obtained.

  28. In vitro release studies • The sample equivalent to 100 mg of atorvastatin calcium was placed in 10 ml of phosphate buffer pH 7.2 it was maintained at 37°C and magnetically stirred at 100rpm. • 2 ml of sample aliquot was with drawn at different time intervals and filtered through a 0.45 mm filter

  29. The dissolution media was then replaced with 2 ml of fresh buffer. • The atorvastatin calcium concentration was determined by HPLC using ODS, C18 column with flow rate of 1ml/min at 250 nm

  30. In vitro Dissolution study of colloidal particles

  31. In vitro drug release study of colloidal particles

  32. In vivo Pharmacokinetic Study of atorvastatin colloidal particles • Procedure was carried with the approval from animal ethical committee • CPCSEA/IAEC approved detail 10/14-CLBMCP/2005-2006. • Male rabbits weighing about 1 kg to 1.5 kg were used in this study

  33. The animals were housed under standard environmental conditions (23°C  2°C, 55  5% relative humidity; 12 hours light/ dark cycle). • Prior to oral administration, the rabbits were starved for 24 hours and are allowed free access to tap water only.

  34. The animals (12) were divided into two groups of 6 animals in each group. • Group- I received standard drug of atorvastatin calcium 2.4mg/kg dose • Group – II received F4 HO, L particles equivalent to 2.4 mg/kg

  35. 1ml blood sample were with drawn from the marginal ear vein of the rabbit at regular time interval. • The serum samples were separated by centrifugation and estimated by using HPLC method.

  36. Comparison of In vivo pharmacokinetic release study

  37. In vivo pharmacokinetic parameters

  38. Pharmacodynamic Study • Procedure was carried with approval from animal ethical committee • CPCSEA/IAEC approved detail 10/15-CLBMCP/2005-2006. • The rats were divided into two groups A and B • Group A and B received high fat diet (HFD)

  39. group A was treated with standard drug • group B received the formulation F4 colloidal particles of atorvastatin calcium orally, administered. • At the end of experimental period all the animals were fasted over night and blood was with drawn.

  40. The total lipids (TL), total cholesterol (TC), triglycerides (TG), phospholipids (PL) and HDl. Cholesterol were estimated in the serum, using commercially available standard kits.

  41. In vivo Pharmocodynamic study

  42. SUMMARY • In the present study an attempt has made to increase the bio availability of the drug by preparing colloidal particles using different drug to polymer ratio to determine the suitable formation.

  43. Atorvastatin calcium colloidal particles was prepared by using emulsification solvent evaporation technique to achieve maximum drug content. • The Prepared Colloidal particle were evaluated for drug content, drug loading and encapsulation efficiency.

  44. F4Ho, L particles showed smooth spherical shape. • Therefore F4Ho, L were subjected to particle size analysis • The in vitro drug release from F4Ho, L shows the maximum release studies after 24 hrs.

  45. In vivo pharmacokinetic study results revealed that the formulation F4 shows better Cmax, tmax, AUC, AUMC and MRT, than the standard drug. • The in vivo pharmacodynamic study shows significance decrease in lipidaemic parameters in rats with formulation F4 than these administered with standard atorvastatin calcium.

  46. To conclude, colloidal particles of atorvastatin calcium improved bioavailability of the drug. • The relative Bio-availability is 1.27 and it is proved by pharmacokinetic and pharmacodynamic studies.

  47. THANK YOU

More Related